Churchill Financial Advisors LLC Invests $4.67 Million in AbbVie Inc. $ABBV

Key Points

• Churchill Financial Advisors initiated a new position in AbbVie during the fourth quarter, buying 20,429 shares valued at about $4.67 million. AbbVie now makes up roughly 1.4% of the firm’s portfolio.
• AbbVie continues to attract broad institutional support, with several large investors increasing their stakes and 70.23% of shares currently held by institutions and hedge funds. Notable buyers included Wellington Management, Vanguard, Raymond James, AllianceBernstein, and Amundi.
• The company’s recent news flow is largely positive, including a positive CHMP opinion in Europe for MAVIRET in acute hepatitis C, encouraging aesthetics and oncology developments, and a Q1 earnings beat with $2.65 EPS versus $2.59 expected.

Churchill Financial Advisors LLC purchased a new position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 20,429 shares of the company's stock, valued at approximately $4,668,000. AbbVie accounts for about 1.4% of Churchill Financial Advisors LLC's investment portfolio, making the stock its 17th biggest position.

A number of other institutional investors and hedge funds have also made changes to their positions in ABBV. Wellington Management Group LLP raised its position in shares of AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the period. Vanguard Group Inc. raised its position in shares of AbbVie by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock worth $41,306,353,000 after purchasing an additional 3,032,438 shares during the period. Raymond James Financial Inc. raised its position in shares of AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company's stock worth $1,733,222,000 after purchasing an additional 2,753,312 shares during the period. Alliancebernstein L.P. raised its position in shares of AbbVie by 31.8% during the 3rd quarter. Alliancebernstein L.P. now owns 7,281,327 shares of the company's stock worth $1,685,918,000 after purchasing an additional 1,758,657 shares during the period. Finally, Amundi raised its position in shares of AbbVie by 15.6% during the 3rd quarter. Amundi now owns 10,508,317 shares of the company's stock worth $2,418,909,000 after purchasing an additional 1,414,621 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie received a positive opinion from the European Medicines Agency’s CHMP for MAVIRET in acute hepatitis C, a potential label expansion that could broaden the drug’s commercial opportunity in Europe. Article Title
• Positive Sentiment: Allergan Aesthetics, an AbbVie company, also secured a positive CHMP opinion for Boey, adding another potential European growth catalyst for AbbVie’s aesthetics business. Article Title
• Positive Sentiment: AbbVie highlighted new oncology data at ASCO 2026, signaling continued momentum across its next-generation cancer pipeline and supporting longer-term growth expectations. Article Title
• Positive Sentiment: Analyst and media commentary remained constructive, with pieces calling AbbVie a strong dividend pick and a long-term buy, which can reinforce investor confidence in the stock. Article Title
• Neutral Sentiment: AbbVie plans 85 summer layoffs in California tied to its Allergan Aesthetics unit, a cost-cutting move that may draw attention but is not large enough on its own to materially change the investment case. Article Title

AbbVie Price Performance

ABBV opened at $216.02 on Monday. AbbVie Inc. has a 12 month low of $181.71 and a 12 month high of $244.81. The stock has a market cap of $381.65 billion, a P/E ratio of 106.41, a P/E/G ratio of 0.74 and a beta of 0.32. The stock's 50 day moving average price is $208.72 and its 200 day moving average price is $219.73.

AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to analysts' expectations of $14.72 billion. During the same period last year, the firm earned $2.46 EPS. The firm's revenue was up 12.4% compared to the same quarter last year. Equities analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ABBV. The Goldman Sachs Group reiterated a "neutral" rating and set a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. Bank of America upgraded AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 price target on the stock in a research report on Thursday, April 30th. Cantor Fitzgerald reiterated an "overweight" rating and set a $240.00 price target on shares of AbbVie in a research report on Thursday, April 30th. Morgan Stanley increased their price target on AbbVie from $270.00 to $278.00 and gave the stock an "overweight" rating in a research report on Thursday, April 30th. Finally, Piper Sandler raised their target price on AbbVie from $294.00 to $298.00 and gave the company an "overweight" rating in a research report on Thursday, May 14th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, AbbVie has a consensus rating of "Moderate Buy" and a consensus price target of $253.43.

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.06% of the company's stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.